Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis

Nucleic Acids Research

Volumn 43, Issue 4, 2015, Pages 2259-2270

  Betancor, Gilberto ^a,c   Alvarez, Mar ^a   Marcelli, Barbara ^a,d   Andres, Cristina ^a,b,e   Martinez, Miguel A ^b   Menendez Arias, Luis ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA; ETRAVIRINE; NITRILE; PURINE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RIBONUCLEASE H; RILPIVIRINE; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA PRIMERS;

ANTIVIRAL RESISTANCE; BIOSYNTHESIS; CHEMISTRY; DNA TEMPLATE; GENETICS; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE;

ANTI-HIV AGENTS; DNA; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; MUTATION; NITRILES; PROTEIN STRUCTURE, TERTIARY; PURINES; PYRIDAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; RILPIVIRINE; RNA; TEMPLATES, GENETIC;

EID: 84945191833     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv077     Document Type: Article

References (51)

1. Menéndez-Arias, L. (2002) Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci., 23, 381-388.
2. Sarafianos, S.G., Marchand, B., Das, K., Himmel, D.M., Parniak, M.A., Hughes, S.H., Arnold, E. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol., 385, 693-713.
3. Menéndez-Arias, L. (2013) Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res., 98, 93-120.
4. Herschhorn, A., Hizi, A. (2010) Retroviral reverse transcriptases. Cell. Mol. Life Sci., 67, 2717-2747.
5. Matamoros, T., Á lvarez, M., Barrioluengo, V., Betancor, G., Menéndez-Arias, L. (2011) Reverse transcriptase and retroviral replication. In: Ku?síc-Ti?sma, J (ed). DNA Replication and Related Cellular Process. InTech, Rijeka, Croatia, pp. 111-142.
6. Sluis-Cremer, N. (2014) The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors. Viruses, 6, 2960-2973.
7. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A., Steitz, T.A. (1992) Crystal structure at 3.5 ?A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science, 256, 1783-1790.
8. Ren, J., Esnouf, R., Garman, E., Somers, D., Ross, C., Kirby, I., Keeling, J., Darby, G., Jones, Y., Stuart, D. et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol., 2, 293-302.
9. Ren, J., Stammers, D.K. (2008) Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res., 134, 157-170.
10. Spence, R.A., Kati, W.M., Anderson, K.S., Johnson, K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science, 267, 988-993.
11. Spence, R.A., Anderson, K.S., Johnson, K.A. (1996) HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry, 35, 1054-1063.
12. Palaniappan, C., Fay, P.J., Bambara, R.A. (1995) Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem., 270, 4861-4869.
13. Hang, J.Q., Li, Y., Yang, Y., Cammack, N., Mirzadegan, T., Klumpp, K. (2007) Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun., 12, 341-350.
14. Radzio, J., Sluis-Cremer, N. (2008) Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol., 73, 601-606.
15. Delviks-Frankenberry, K.A., Nikolenko, G.N., Pathak, V.K. (2010) The 'connection' between HIV drug resistance and RNase H. Viruses, 2, 1476-1503.
16. Abbondanzieri, E.A., Bokinsky, G., Rausch, J.W., Zhang, J.X., Le Grice, S.F.J., Zhuang, X. (2008) Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature, 453, 184-189.
17. Liu, S., Abbondanzieri, E.A., Rausch, J.W., Le Grice, S.F.J., Zhuang, X. (2008) Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science, 322, 1092-1097.
18. Grobler, J.A., Dornadula, G., Rice, M.R., Simcoe, A.L., Hazuda, D.J., Miller, M.D. (2007) HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J. Biol. Chem., 282, 8005-8010.
19. Biondi, M.J., Beilhartz, G.L., McCormick, S., Götte, M. (2010) N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. J. Biol. Chem., 285, 26966-26975.
20. Gopalakrishnan, V., Benkovic, S. (1994) Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase. J. Biol. Chem., 269, 4110-4115.
21. Shaw-Reid, C.A., Feuston, B., Munshi, V., Getty, K., Krueger, J., Hazuda, D.J., Parniak, M.A., Miller, M.D., Lewis, D. (2005) Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry, 44, 1595-1606.
22. Lapkouski, M., Tian, L., Miller, J.T., Le Grice, S.F.J., Yang, W. (2013) Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat. Struct. Mol. Biol., 20, 230-236.
23. Nikolenko, G.N., Palmer, S., Maldarelli, F., Mellors, J.W., Coffin, J.M., Pathak, V.K. (2005) Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. U.S.A., 102, 2093-2098.
24. Delviks-Frankenberry, K.A., Nikolenko, G.N., Barr, R., Pathak, V.K. (2007) Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3-azido-3-deoxythymidine resistance. J. Virol., 81, 6837-6845.
25. Hachiya, A., Kodama, E.N., Sarafianos, S.G., Schuckmann, M.M., Sakagami, Y., Matsuoka, M., Takiguchi, M., Gatanaga, H., Oka, S. (2008) Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol., 82, 3261-3270.
26. Nikolenko, G.N., Delviks-Frankenberry, K.A., Pathak, V.K. (2010) A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol., 84, 5238-5249.
27. Menéndez-Arias, L., Betancor, G., Matamoros, T. (2011) HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Res., 92, 139-149.
28. Gupta, S., Fransen, S., Paxinos, E.E., Stawiski, E., Huang, W., Petropoulos, C.J. (2010) Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance. Antimicrob. Agents Chemother., 54, 1973-1980.
29. Gupta, S., Vingerhoets, J., Fransen, S., Tambuyzer, L., Azijn, H., Frantzell, A., Paredes, R., Coakley, E., Nijs, S., Clotet, B. et al. (2011) Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens. Antimicrob. Agents Chemother., 55, 2872-2879.
30. Yap, S.-H., Sheen, C.-W., Fahey, J., Zanin, M., Tyssen, D., Lima, V.D., Wynhoven, B., Kuiper, M., Sluis-Cremer, N., Harrigan, P.R. et al. (2007) N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med., 4, e335.
31. Paredes, R., Puertas, M.C., Bannister, W., Kisic, M., Cozzi-Lepri, A., Pou, C., Bellido, R., Betancor, G., Bogner, J., Gargalianos, P. et al. (2011) A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J. Infect. Dis., 204, 741-752.
32. Schuckmann, M.M., Marchand, B., Hachiya, A., Kodama, E.N., Kirby, K.A., Singh, K., Sarafianos, S.G. (2010) The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. J. Biol. Chem., 285, 38700-38709.
33. Ehteshami, M., Beilhartz, G.L., Scarth, B.J., Tchesnokov, E.P., McCormick, S., Wynhoven, B., Harrigan, P.R., Götte, M. (2008) Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3-azido-3-deoxythymidine through both RNase H-dependent and-independent mechanisms. J. Biol. Chem., 283, 22222-22232.
34. Matamoros, T., Deval, J., Guerreiro, C., Mulard, L., Canard, B., Menéndez-Arias, L. (2005) Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by-phosphate-modified thymidine analogues. J. Mol. Biol., 349, 451-463.
35. Boretto, J., Longhi, S., Navarro, J.-M., Selmi, B., Sire, J., Canard, B. (2001) An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase. Anal. Biochem., 292, 139-147.
36. Kati, W.M., Johnson, K.A., Jerva, L.F., Anderson, K.S. (1992) Mechanism and fidelity of HIV reverse transcriptase. J. Biol. Chem., 267, 25988-25997.
37. Betancor, G., Puertas, M.C., Nevot, M., Garriga, C., Mart?nez, M.A., Martinez-Picado, J., Menéndez-Arias, L. (2010) Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure. Antimicrob. Agents Chemother., 54, 4799-4811.
38. Kellam, P., Larder, B.A. (1994) Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother., 38, 23-30.
39. Huber, H.E., Richardson, C.C. (1990) Processing of the primer for plus strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem., 265, 10565-10573.
40. Rausch, J.W., Le Grice, S.F.J. (2004) 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus. Int. J. Biochem. Cell Biol., 36, 1752-1766.
41. GÖtte, M., Kameoka, M., McLellan, N., Cellai, L., Wainberg, M.A. (2001) Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription. J. Biol. Chem., 276, 6711-6719.
42. Xu, H.T., Colby-Germinario, S.P., Oliveira, M., Han, Y., Quan, Y., Zanichelli, V., Wainberg, M.A. (2014) The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity. J. Virol., 88, 1536-1547.
43. Das, K., Clark, A.D. Jr, Lewi, P.J., Heeres, J., De Jonge, M.R., Koymans, L.M., Vinkers, H.M., Daeyaert, F., Ludovici, D.W., Kukla, M.J. et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem., 47, 2550-2560.
44. Das, K., Bauman, J.D., Clark, A.D. Jr, Frenkel, Y.V., Lewi, P.J., Shatkin, A.J., Hughes, S.H., Arnold, E. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistant mutations. Proc. Natl. Acad. Sci. U.S.A., 105, 1466-1471.
45. Lansdon, E.B., Brendza, K.M., Hung, M., Wang, R., Mukund, S., Jin, D., Birkus, G., Kutty, N., Liu, X. (2010) Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J. Med. Chem., 53, 4295-4299.
46. Chung, S., Miller, J.T., Lapkouski, M., Tian, L., Yang, W., Le Grice, S.F.J. (2013) Examining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids. J. Biol. Chem., 288, 16177-16184.
47. Sarafianos, S.G., Das, K., Tantillo, C., Clark, A.D. Jr, Ding, J., Whitcomb, J.M., Boyer, P.L., Hughes, S.H., Arnold, E. (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J., 20, 1449-1461.
48. Das, K., Martinez, S.E., Bauman, J.D., Arnold, E. (2012) HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat. Struct. Mol. Biol., 19, 253-259.
49. Rausch, J.W., Lener, D., Miller, J.T., Julias, J.G., Hughes, S.H., Le Grice, S.F.J. (2002) Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochemistry, 41, 4856-4865.
50. Wright, D.W., Deuzing, I.P., Flandre, P., van den Eede, P., Govaert, M., Setiawan, L., Coveney, P.V., Marcelin, A.-G., Calvez, V., Boucher, C.A.B. et al. (2013) A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNase H activity. PLoS One, 8, e74078.
51. Vijayan, R.S., Arnold, E., Das, K. (2014) Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations. Proteins, 82, 815-829.